Associated Papers
Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine.
Gorodetska I et al.
Familial Cancer, 2017
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Zhen DB et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2015
BRCA1 germline mutations may be associated with reduced ovarian reserve.
Wang ET et al.
Fertility and Sterility, 2014
Pyrimidine base damage is increased in women with BRCA mutations.
Budzinski EE et al.
Cancer Letters, 2013
Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review.
Oluwagbemiga LA et al.
Springerplus, 2012
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
Bayraktar S et al.
Cancer, 2012
Earlier age of onset of BRCA mutation-related cancers in subsequent generations.
Litton JK et al.
Cancer, 2012
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D et al.
Jama, 2011
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
Adams S et al.
Cancer Immunology, Immunotherapy : Cii, 2011
Integrated genomic analyses of ovarian carcinoma.
Unknown Author
Nature, 2011
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.
Hall MJ et al.
Cancer, 2009
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Dworkin AM et al.
Familial Cancer, 2009
Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
Miramar MD et al.
Breast Cancer Research and Treatment, 2008
[BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases].
Hu Z et al.
Zhonghua Yi Xue Za Zhi, 2008
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2006
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T et al.
Cancer, 2005
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
Kroiss R et al.
Human Mutation, 2005
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R et al.
Jama, 2005
Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
Leegte B et al.
Journal of Medical Genetics, 2005
Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1.
Eng C et al.
Journal of Medical Genetics, 2001
Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA et al.
Human Mutation, 2001
Genetic testing for breast-ovarian cancer susceptibility: a regional trial.
Loader S et al.
Genetic Testing, 1998
Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Vehmanen P et al.
Human Molecular Genetics, 1997